Since 2013, Novadip Biosciences has been developing breakthrough innovations in cell-based therapies for hard and soft tissue. While our first mission was to treat patients with bone defects and bone diseases, our adipose stem cell-based technology now offers potential for further applications, including skin regeneration.
Pre-Clinical And Clinical Data
Two proof of concept studies for NVD-001 on relevant animal models (pigs) and clinical data from 10 patients requiring orthopaedic surgery treated with first generation NVD-001 with authorization of the Ethical Committee of the participating hospital (Medical Faculty of Catholic University of Louvain, Brussels, Belgium) are available to support development. Similarly, for NVD-002, 7 patients with non-healing wounds have already been treated.
Novadip runs state-of-the-art grade A/B cleanrooms for GMP production of clinical batches to support upcoming clinical developments.
The GMP manufacturing process for the product pipelines is simple, robust, fully controlled and scalable.
Demonstration Of Clinical Safety & Efficacy
Outcomes of clinical cases performed in the academic setting showed unseen clinical efficacy without significant side effect, even in salvage cases.